Quracle confirms proteinuria 35.2% reduction · Dong-A ST’s P-CAB 2place

Quracle announced that 2026year 6month 8day clinical results for its kidney disease treatment showed proteinuria had decreased by up to 35.2%. The company said it had disclosed the clinical results. It said specific patient numbers and additional indicators could be confirmed through the company’s announcement.

Dong-A ST announced that on 2026year 6month 8day, its treatment for gastroesophageal reflux disease ranked 2place in the domestic P-CAB market. The company announced the product name and the fact that it achieved the ranking. It said detailed information, including the market share figure, was included in the announcement.

Dong-A ST said on the same day that the diabetes drug ‘Dapagpro’ had demonstrated non-inferiority compared with Forxiga. The company said it had confirmed non-inferiority based on the clinical comparison results. It said the clinical design and statistical grounds were presented in the announcement.

Daewoong 2026year 6month 8day announced that the diabetes drug Enblo had shown efficacy in patients across multiple countries. The company said it had confirmed the efficacy based on multinational data. It said the specific countries and number of patients were stated in the company’s announcement.

The joint investigation headquarters of the prosecution and police is discussing the direction of its future investigation in connection with the shortage of ballots. The headquarters said it was reviewing the investigation methods and where responsibility lies. It said details such as the investigation schedule and whether additional personnel would be deployed would be announced later.

All of these announcements were made on 2026year 6month 8day. Each company and investigative agency is providing additional materials and details through its announcement. Investors and other stakeholders can check the full text of the relevant announcements.